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Summary
Short-chain fatty acid (SCFA)-carbohydrate hybrid
molecules that target both histone deacetylation
and glycosylation pathways to achieve sugar-depen-
dent activity against cancer cells are described in
this article. Specifically, n-butyrate esters of N-ace-
tyl-D-mannosamine (But4ManNAc, 1) induced apopto-
sis, whereas corresponding N-acetyl-D-glucosamine
(But4GlcNAc, 2), D-mannose (But5Man, 3), or glycerol
(tributryin, 4) derivatives only provided transient cell
cycle arrest. Western blots, reporter gene assays,
and cell cycle analysis established that n-butyrate,
when delivered to cells via any carbohydrate scaffold,
functioned as a histone deacetylase inhibitor (HDACi),
upregulated p21WAF1/Cip1 expression, and inhibited
proliferation.However, only 1, a compound thatprimed
sialic acid biosynthesis andmodulated the expression
of a different set of genes compared to 3, ultimately
killed the cells. These results demonstrate that the
biological activity of butyrate can be tuned by sugars
to improve its anticancer properties.
Introduction
This article describes compounds that target two hall-
marks of cancer: the loss of cell cycle checkpoint con-
trol [1] and abnormal glycosylation [2, 3]. Uncontrolled
cell proliferation characteristic of transformed cells is,
in part, epigenetic in origin, and results from cancer-
specific anomalies in chromatin structure [4, 5]. Chro-
matin consists of DNA, histones, and accessory
proteins, such as histone deacetylase (HDAC) and his-
tone acetyltransferase (HAT). Together, HDAC and
HAT remodel chromatin to provide a ‘‘code’’ recognized
by nonhistone proteins that regulate gene expression
[4]. Not surprisingly, there is intense interest in the pre-
cise mechanisms that regulate chromatin remodeling,
with the bulk of these efforts focused on the inhibition
of HDACs. In recent years, the ability of HDAC inhibitors
(HDACi) to disrupt cell cycle progression or selectively
induce apoptosis via derepression of genes, such as
*Correspondence: kyarema1@jhu.eduP21 and BAX, in cancer cells has made HDAC inhibition
an attractive avenue for the development of anticancer
drugs [6–8].
n-Butyrate, a naturally-occurring HDACi belonging to
the class of compounds known as short-chain fatty acids
(SCFAs) [9], has selective activity toward transformed
cells compared with healthy cells [10]. Efforts to exploit
n-butyrate for clinical treatment of cancer, however,
have been stymied by its poor pharmacological proper-
ties and the high concentrations (up to 50 mM) needed
for bioactivity [11]. One approach to avoid the pharma-
cokinetic limitations of n-butyrate has been to use tradi-
tional enzyme-substrate screening assays to discover
‘‘drug-like’’ small-molecule HDACi, such as trichostatin,
suberoylanilide hydroxamic acid (SAHA), and MS-275,
among others [7]. These compounds inhibit cell growth,
induce terminal differentiation, and prevent tumor for-
mation in animal models [12]. Despite these attractive
anticancer properties and nanomolar binding affinities
when tested against purified enzyme, the majority of cur-
rent HDACi clinical candidates require unrealistically
high (up to millimolar) concentrations to be effective
against cells [4].
A strategy to improve the pharmacological properties
of HDACi has been to structurally modify n-butyrate to
increase cellular uptake. A prominent example of this
approach is 4-phenylbutyrate (4PB), which is an FDA-
approved (albeit for urea cycle disorders, not cancer
[13, 14]) and ‘‘generally well tolerated’’ derivative of n-
butyrate [15]. Despite the relative safety of 4PB, second-
ary metabolites [16] and a relatively modest gain in effi-
ciency (w2- to 10-fold) reduce prospects for its clinical
application. In another approach, n-butyrate is delivered
in the form of prodrugs as an arginine salt or as esters of
lactic acid and cholesterol to enhance cellular uptake
and retention. Perhaps the most successful compound
where n-butyrate is delivered as a monovalent ester
has been pivaloyloxymethyl butyrate (Pivanex, or AN-
9) [17], which showed modest efficacy against non-
small cell lung cancer in Phase II trials [18].
Based on the enduring difficulties in supplying HDACi
to cells at sufficiently high concentrations to support
bioactivity, prodrugs have been studied where carbo-
hydrate moieties function as multivalent ‘‘cores’’ for the
simultaneous delivery of several n-butyrate molecules.
Specific examples of n-butyrate delivered via sugar-
appended esters include straight-chain threitol and
tributyrin cores (glycerol tributyrate, 4) [19], as well as the
cyclic scaffolds glucose [20], galactose, mannose, and
xylitol [21, 22]. Over the past 2 decades, these strategies
have shown sufficient promise in clinical tests to support
continuing investigation, but a breakthrough justifying
widespread clinical use remains elusive [6]. We reasoned
that one factor hindering progress was that carbohydrate
scaffolds have served only as innocuous delivery vehi-
cles; by contrast, we proposed that by appropriate selec-
tion of the monosaccharide, the activity of n-butyrate
could be augmented through glycosylation pathways.
Although glycosylation-based therapies for cancer
have been slow to emerge, growing evidence of the
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1266Figure 1. Sugar-Dependent Targeting of
Glycosylation and Cell Cycle Progression
(A) Schematic diagram showing the cellular
uptake of 1, intracellular release of butyrate
and ManNAc, and the sialic acid biosynthetic
pathway related activity resulting in cell
cycle arrest and apoptosis.
(B) Structures of butyrate-carbohydrate
hybrid compounds studied in this report.many roles of sugars in the carcinogenic transformation
of cells [23, 24] has established oligosaccharide path-
ways as a rich and largely untapped opportunity to im-
prove cancer treatments [3, 25, 26]. Although nascent
efforts are under way to develop cancer vaccines and
immunotherapies [27, 28] based on glycoconjugate
structures used as biomarkers to distinguish cancer
cells from their healthy counterparts [24, 29], actual in-
tervention in the biochemical pathways responsible for
cancer-specific glycosylation defects is almost nonexis-
tent. The strategy of using a sugar as a delivery vehicle
for HDACi, however, opens the door for targeting glyco-
sylation pathways. In particular, we reasoned that the
hexosamines (6-carbon amino sugars) that cells employ
for building the oligosaccharides [30] that characterize
both healthy and diseased cells and exert influence
over cell signaling pathways involved in cancer [31]
could be modulated to influence the activity of butyrate.
There are three predominant hexosamines in human
cells, and each is relevant to cancer biology. First,N-ace-
tylglucosamine (GlcNAc) forms the anchoring residues
forN-linked oligosaccharides, which are often aberrantly
displayed on cancer cells [29]. GlcNAc also plays a sec-
ond, intracellular role in cancer through the addition and
removal of O-GlcNAc on oncoproteins, tumor suppres-
sors, and other proteins involved in the pathogenesis
of tumors [32]. Second,N-acetylgalactosamine (GalNAc)
is the chain initiator forO-glycosylated proteins, and ab-
errantO-glycan chains found in cancer often expose pre-
viously masked glycans or peptide motifs as new anti-genic targets [31], such as mucins [33, 34]. Finally,
a third hexosamine tied to cancer is N-acetylmannos-
amine (ManNAc); this sugar is the focus of this study
and illustrates the value of considering carbohydrate
expression while designing drugs for cancer treatment.
ManNAc has several attractive features that led us
to select it as the lead hexosamine for drug develop-
ment. First, it is a committed precursor for the sialic
acid biosynthetic pathway, thus enabling the targeting
of a single biochemical pathway [35, 36]. Second, by
altering flux through the sialic acid biosynthetic pathway
[37], ManNAc changes sialyltransferase and sialidase
activity [38] and alters the display of sialic acid on cell
surface glycoproteins [39, 40] and glycolipids [41, 42].
Because sialoglycans modulate apoptosis [39–43], we
reasoned that the cell cycle inhibitory properties of
n-butyrate could be enhanced in combination with
changes to sialic acid metabolism (Figure 1A) by using
the hybrid molecule, But4ManNAc (1, Figure 1B), known
to efficiently increase sialic acid production in cells [44].
In this article, we show that butyrate gains a unique abil-
ity to induce apoptosis when presented to cells as 1, and
demonstrate that 1 has characteristic SCFA activity and
activates sialic acid biosynthesis, as expected, due to
its butyrate and ManNAc components, respectively.
In control experiments, delivery of n-butyrate via other
carbohydrate scaffolds only gave transient growth inhi-
bition, illustrating the necessity of targeting a specific
glycosylation pathway—in this case, sialic acid biosyn-
thesis—to achieve the desired sugar-dependent activity.
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1267Figure 2. Arrest and Execution of Cancer
Cells by Compound 1, But4ManNAc
(A) Short-term (Days 3 and 5) and long-term
(Day 15) growth characteristics of Jurkat
cells incubated with 1–4; treatment with 1 in-
duces both growth arrest and cell death,
whereas cells treated with either 2, 3, or 4
resumed cell growth over the long term.
(B) Growth characteristics of Jurkat cells
incubated with 5.
(C) Trypan blue cell viability assay of Jurkat
cells incubated with 1–3 at 200 mM.
(D) Effect of 1–4 on growth characteristics of
HL-60 cells on Day 15. Standard deviations
of three replicate experiments were less
than 10%, and the error bars were omitted
for clarity.Importantly, the full effects of 1 could not be reproduced
by concurrently delivering butyrate and ManNAc as
separate molecules, indicating that the hybrid mole-
cules are critical for achieving the novel bioactivities
described here.
Results and Discussion
Butyrate-Induced Cell Death Is Dependent
on the Core Sugar Moiety
To test the hypothesis that monosaccharides tune
the activity of butyrate, perbutyrate derivatives of N-
acetyl-D-mannosamine (But4ManNAc, 1, Figure 1B) and
two control monosaccharides (N-acetyl-D-glucosamine
[But4GlcNAc, 2] and D-mannose [But5Man, 3]) were syn-
thesized (see the Supplemental Data available with this
article online) and tested on human cancer cells. To
briefly explain the rationale for the controls, 2 is the C2
epimer of 1 that, if anything, should be protective via
the O-GlcNAc protein modification antistress mecha-
nism [45], and 3 is the oxygen analog of 1 (i.e., it has
an 2OH group in place of the N-acetyl group at C2)
that does not enter the sialic acid pathway. Finally, trib-
utyrin (4) and sodium n-butyrate (5), compounds that
have already undergone clinical evaluation [19], pro-
vided benchmarks for SCFA-based HDACi activity.
In initial assays, Jurkat (human T lymphoma) cells
were incubated with 1–5, and growth rates were moni-
tored. As expected from the ability of butyrate to arrest
cell cycle progression, reduced proliferation occurred
when cells were incubated with 1–3 for 3–5 days(Figure 2A), while 4 and 5 showed minimal inhibition
under the same conditions (Figures 2A and 2B). Despite
similar cell counts at days 3 and 5 for 1–3, trypan blue as-
says hinted that the underlying biological response to
these compounds was different, as 1, but not 2 or 3,
led to reduced cell viability (Figure 2C). Continued incu-
bation amplified the early differences in cell viability, as,
by day 15, cells treated with 2–5 resumed robust growth,
whereas cells died when treated with 1 at concentra-
tionsR 70–80 mM. These results indicated that cell cycle
arrest induced by 2–4 up to 320 mM, and by 5 up to
2.0 mM, is transient. By contrast, for 1, the core carbohy-
drate, ManNAc, played a crucial role in preventing long-
term growth recovery and ensuring cell death. To test
whether the sugar-dependent effects between ManNAc
and n-butyrate were general toward cancer cells, 1–4
were evaluated in several human lines, with similar re-
sults (representative data, for the HL-60 line, are given
in Figure 2D).
Hexosamine-Delivered Butyrate Has Characteristic
SCFA Activity
In this article, we provide experimental evidence that the
bioactivity supported by 1, in particular, its unique ability
to ‘‘arrest and execute’’ cells (Figures 1A and 2A), results
from the cooperative effects of n-butyrate groups (which
function as HDACi to provide growth arrest) and
ManNAc (which activates the sialic acid pathway to in-
duce apoptosis). First, we present evidence that 1 is
an efficient delivery agent for biologically active buty-
rate. Based on seminal reports that butyrate induces
Chemistry & Biology
1268Figure 3. Upregulation of p21WAF1/Cip1 by
1–5
(A) SDS-PAGE showing the levels of acety-
lated histone H3 and total histone H3 in
HeLa cells treated with 1–5 for 5 days. Two
independent gels showed similar effects on
the levels of histone H3 acetylation.
(B) Quantitation of levels of acetyl-histone
H3 given as a percentage of total histone
H3 quantified by densitometry using NIH Im-
ageJ. Two replicate gels gave similar results.
(C) Expression of p21WAF1/Cip1 promoter-
driven luciferase in AD293 (HEK) cells tran-
siently transfected with luc-p21WAF1/Cip1
plasmid and subsequently incubated with
1–4, as measured by luminometry. Error
bars are standard deviation of the mean of
at least three replicates.
(D) A time course of the endogenous expres-
sion of p21WAF1/Cip1 in Jurkat cells treated
with 1 or 5 using an anti-p21WAF1/Cip1
antibody and flow cytometry quantification.
Error bars represent standard deviation of
the mean of at least three replicates.differentiation of cancer cells with distinctive morpho-
logical changes [46], we verified the ability of 1 to induce
similar effects in HeLa and AD293 (human embryonic
kidney [HEK]) cells (Figure S1). Next, we used a set of
three complementary assays, western analysis of his-
tone acetylation, activation of gene expression mea-
sured by upregulation of exogenous and endogenous
p21WAF1/Cip1, and analysis of cell cycle progression, to
prove that n-butyrate-sugar hybrids exhibit characteris-
tic SCFA bioactivity.
Based on the precedent provided by per-acetylated
saccharides [37, 47], we anticipated that 1–4 would
have high membrane permeability and efficiently release
n-butyrate inside a cell upon hydrolysis by nonspecific
esterases. As a first step to test whether the sugar-sup-
plied n-butyrate had characteristic SCFA activity, we
monitored the acetylation of histone H3 in HeLa cells in-
cubated with 1–4 by western blotting [48]. As a positive
control for HDACi activity, incubation of cells with 5 at
2.0 mM showed relatively high levels of acetyl histone
H3 (71% of total H3; Figures 3A and 3B). Evaluation of
1–4 at 200 mM led to relative acetylation levels of 50%,
36%, 29%, and 52% for 1, 2, 3, and 4, respectively (Fig-
ures 3A and 3B), verifying that biologically active buty-
rate is released intracellularly. Interestingly, 1 was
a more effective inhibitor than 2 and 3, a result that
held in the next set of assays described below, testing
p21WAF1/Cip1 expression; by contrast, 1 and 4 inhibited
histone deacetylation about equally, but the latter com-
pound was significantly less efficient at activating
p21WAF1/Cip1 expression.
A consequence of HDAC inhibition, a hallmark of
n-butyrate activity, is the upregulation of cell cycle
checkpoint proteins, such as p21WAF1/Cip1. When we
evaluated luciferase activity from a luc-p21WAF1/cip1
reporter plasmid [49] in HEK AD293 cells [50] exposed
to 1–4, expression increased in a dose-dependent
manner (Figure 3C), with 1 showing higher activity than
2–4. Interestingly, the activity of 4 was considerably
lower than the activity of 1, a result that does not corre-
spond to the histone acetylation results where 1 and 4had similar inhibition; this result, combined with the
lack of toxicity for 4 (Figure 2A), clearly indicates that
the ManNAc core of 1 contributed to the bioactivity of
this compound by enhancing the effects of n-butyrate.
To test whether p21WAF1/Cip1-promoter activation held
across cell lines and for endogenous p21WAF1/Cip1, p21
levels were evaluated by flow cytometry [51] in Jurkat
cells, and were found to increase in cells treated with
both 1 and 5 (Figure 3D). Of practical importance for
drug development efforts, endogenous p21WAF1/Cip1
gene activation was achieved at considerably (w103)
lower concentrations for 1 than for 5 (Figure 3D).
Having confirmed that 1–5 activated p21WAF1/Cip1-
driven gene expression consistent with the known activ-
ity of SCFAs, we next tested whether these compounds
also blocked cell cycle progression at the G2/M (4n)
stage [52]. Standard propidium iodide (PI)/ribonuclease
A (RNase A) assays [53] in asynchronous Jurkat cells
showed that cell accumulation at the G2/M stage oc-
curred after incubation with 2–4 (5 days, 200 mM) without
measurable apoptosis (Figure 4A). In contrast, the ma-
jority of cells treated with 1 appeared to be apoptotic
(< 2n), with very few remaining at the G0/G1 (2n) stage.
At lower concentrations (0–75 mM), however, 1 sup-
ported a stepwise decrease in G0/G1 accumulation,
with a concomitant increase in cells at the G2/M stage,
consistent with known ability of butyrate to arrest
cell cycle progression (Figure 4B). Nonviable cells
(sub-G0) accumulated when concentrations of 1 ex-
ceeded 75 mM, the concentration required for cell death
after 15 days of exposure (Figure 2A).
A time- and concentration-dependent comparison of
Jurkat cells treated with 1 provided results (Figure 5)
consistent with the growth inhibition and trypan blue
toxicity data presented earlier (in Figure 2C). Control
cells showed little change in cell cycle status up to
day 4, after which a minor increase in cells at the
G0/G1 stage was seen due to growth saturation that
occurred upon reaching a density of > 2.0 3 106 cells/
ml (Figure 5A). Upon treatment with 100 mM of 1
(Figure 5B), there was strong cell cycle inhibition at the
Targeting Glycosylation and Cell Cycle
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increasing number of cells with less than 2n (i.e., frag-
mented) DNA. At 200 mM (Figure 5C), cells accumulated
rapidly at the G2/M stage, with a concomitant decrease
in the G0/G1 stage. Significantly, by day 4, a substantial
proportion of the cells showed DNA in the sub-G0 range;
by day 6, this response was almost complete. DNA
fragmentation in the sub-G0 range is consistent with
chromosomal degradation that occurs in apoptosis;
therefore, the sub-G0 accumulation seen here upon
treatment with 1, combined with our previous extensive
characterization of ManNAc analog-induced apoptosis
in Jurkat cells [44, 54], strongly indicated that this com-
pound killed cells through an apoptotic mechanism.
Nonetheless, to obtain direct evidence of apoptosis,
we measured caspase-3 activity [44] in Jurkat cells
incubated with 25, 50, and 100 mM of 1 for 48 hr, and
found increases of w4-, 8-, and 14-fold, respectively
(Figure S2).
The Unique Activity of 1 Cannot Be Reproduced
by Its ManNAc and n-Butyrate Components
The results of the toxicity assays, western blotting,
p21WAF1/cip1 expression, and cell cycle studies reported
above established that 1was an efficient delivery vehicle
for introducing biologically active n-butyrate into cells,
and had a unique ability to induce apoptosis. We were
interested in exploring whether the advantages of
1 simply resulted from this compound acting as a better
Figure 4. Cell Cycle Arrest and Apoptosis
(A) Flow cytometry histograms showing DNA content and cell cycle
status of Jurkat cells incubated with 1–4 at 200 mM for 5 days mea-
sured by PI/RNase A staining.
(B) DNA content of Jurkat cells incubated with 1 at 25–150 mM, for
5 days, showing a dose-dependent increase in the population of
apoptotic cells.delivery agent for n-butyrate than the other derivatives;
this possibility was suggested by the luciferase reporter
assay data (Figure 3A), where 1 hadw50% higher activ-
ity at 100 mM than 2 or 3. This result was counterintuitive,
because 3 delivered five butyrate equivalents into a cell,
whereas 1 only delivered four. One—albeit unlikely—
possibility to explain this result was that ManNAc
increased the efficiency of butyrate through mecha-
nisms unrelated to its direct attachment to this SCFA
via ester linkages; for example, through an allosteric
increase in membrane transport activity. In order to
discount such a possibility, we tested luc-p21WAF1/ Cip1
expression after incubating cells with a mixture of
free monosaccharide form of ManNAc and 5 in a 1:4 ratio
designed to mimic the relative molar ratios of the sugar
and butyrate moieties in 1. The supplementation of
5 with ManNAc had no effect on luciferase activity,
which required millimolar concentrations of each com-
pound (Figure 6A), indicating that the ability of 1 to
activate butyrate-specific gene expression patterns at
micromolar concentrations was contingent upon sup-
plying the sugar and SCFA functionalities in the same
molecule.
A clue for the unique ability of 1 to induce apoptosis
emerged from a comparison of the toxicity data for cells
treated with 1–3 with the results of the luciferase re-
porter gene assay. Specifically, at 50 mM and below,
none of these three compounds were toxic after 15
days (Figures 2A–2C), and they all showed similar acti-
vation of p21WAF1/Cip1 expression (Figure 3C) in this
concentration range. Interestingly, gene activation for
1 continued to increase significantly between 50 and
100 mM for 1, whereas the corresponding increase was
slight for 2 or 3; importantly, apoptosis associated with
1 (Figure 2A) also occurred over this concentration
range, suggesting that a threshold of p21WAF/Cip1
activation—not reached by 2 or 3 (Figure 3C)—may be
required for toxicity. Another nonexclusive possibility
was that the n-butyrate-specific effects of 1 were aug-
mented by the ability of this compound to support
a rapid increase in sialic acid biosynthesis, which once
again occurred over the same range of concentrations
(Figure 6B).
The data discussed in the previous paragraph illus-
trates that 1 serves the dual role of functioning as an
efficient delivery vehicle for butyrate, evidenced by
p21WAF1/Cip1 activation (Figure 6A), and for ManNAc,
as shown for sialic acid production (Figure 6B). In both
cases, the biological response to 1 took place at much
lower concentrations than when ManNAc and 5 were
concurrently added to cells, but as separate com-
pounds. These experiments, however, did not address
whether supplying these compounds as separate mole-
cules, albeit at higher concentrations, could enhance
apoptosis. This possibility was raised by studies in
which HDACi have been combined with a second drug
to augment their anticancer activity [55]. Accordingly,
we tested whether ManNAc, presumably through its
primary metabolic fate of increasing flux into the sialic
acid pathway, could similarly complement the activity
of butyrate by sensitizing cells to its effects. To this
end, Jurkat cells were incubated with 50 and 100 mM
ManNAc for 48 hr, which increased total levels of sialic
acid by w7- and 9-fold, respectively, compared with
Chemistry & Biology
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and Cell Death
(A) Flow cytometry histograms showing DNA
content and change in cell cycle status of
Jurkat cells over a 6 day period.
(B) DNA content and cell cycle status of
Jurkat cells incubated with 1 at 100 mM.
(C) DNA content and cell cycle status of
Jurkat cells incubated with 1 at 200 mM.untreated controls (Figure 6C). The test cells were then
exposed to 5, and their growth was quantified by cell
counting after 5 days (Figure 6D). The proliferation of
ManNAc-treated cells was inhibited modestly, but in
a statistically significant manner, at concentrations of
5 below 0.5 mM compared with untreated control cells
(Figure 6E). Upon continued incubation, both the control
and ManNAc-treated cells exposed to 1.5 mM and lower
concentrations of 5 recovered and resumed robust
growth by Day 15. The ManNAc-treated cells, however,
showed increased susceptibility to 5 at 2.0 mM com-
pared to the controls (Figure 6F; there was significant
toxicity for all samples when treated with 5 at concentra-
tions higher than 2.5 mM).
The sensitization of cells pretreated with ManNAc to
the effects of butyrate highlighted two important fea-
tures of the strategy exemplified by 1 of using sugar-
SCFA hybrid molecules as anti-cancer agents. First, on
a conceptual level, these results provide experimental
support for the hypothesis that glycosylation pathways
(shown by the activation of sialic acid biosynthesis)
can be exploited to complement the activity of butyrate.
Second, on a practical level, the levels of butyrate (2.0
mM) and ManNAc (50–100 mM) required for even mod-
est growth inhibition (Figure 6E) and toxicity (Figure 6F),
when used separately, exceed realistic drug develop-
ment parameters. The necessity for combining ManNAc
and 5 into a single molecule was reinforced by the inabil-
ity of ManNAc to alter cell cycle status at 10 mM(Figure 6G, top panel). Similarly, the more pharmacolog-
ically realistic level of ManNAc of 125 mM failed to
augment the activity of 5 (Figure 6G, center panels). By
contrast, almost complete DNA fragmentation, which
is indicative of apoptosis, resulted from 100 mM of 1
(Figure 6G, bottom panel).
To recap the inability of the combined administration
of ManNAc and 5 to phenocopy the effects of 1, we
briefly revisit the data presented in Figure 6B. In this ex-
periment, a combination of ManNAc and 5 in the 1:4 ratio
found in 1 did not result in an increase in sialic acid pro-
duction up to the dose-limiting level of a mixture of
5.0 mM ManNAc and 20 mM of 5. ManNAc by itself re-
sulted in a dose-dependent increase in sialic acid pro-
duction between 0.2 and 100 mM to a maximum of
w2.03 1010 molecules/cell. By contrast, sialic acid pro-
duction for cells treated with 1 occurred at much lower
concentrations (between 25 and 100 mM), and reached
double (>4.0 3 1010 molecules/cell) the level achieved
with ManNAc. Importantly, the level of sialic acid pro-
duced in cells treated withw75 mM of 1, the concentra-
tion required for toxicity (Figure 2A), was w4.0 3 1010
molecules/cell. As a result, the free monosaccharide
form of ManNAc leaves a significant shortfall (indicated
by the asterisk in Figure 6B) in the amount of sialic acid
produced compared with cells experiencing the full
toxic effects of 1. Consequently, it is not surprising
that efforts to reproduce the cellular response to this
compound, with its two component moieties, ManNAc
Targeting Glycosylation and Cell Cycle
1271Figure 6. Comparisons of ManNAc and n-Butyrate as the Hybrid Molecule 1 or as Single Molecular Entities Added to Cells in Combination
(A) Comparison of luc-p21WAF1/Cip1 expression in AD293 (HEK) cells treated with either 1 (0–250 mM) or 5 (0–10 mM) alone, or a mixture of 5
(0–10 mM) and ManNAc (0–2.5 mM) at a relative molar ratio of 4:1. In this set of assays, concentrations of the test compounds were increased
until signal-limiting toxicity occurred. Error bars represent standard deviation of at least three replicate samples.
(B) Total sialic acid content, determined by periodate-resorcinol assay [63], in Jurkat cells incubated with either 1 (0–250 mM) or ManNAc
(0–100 mM) alone, or a mixture of ManNAc (0–5 mM) and 5 (0–20 mM) at a molar ratio of 1:4.
(C) Total sialic acid content in Jurkat cells primed for increased sialic acid production by incubation with 0, 50, and 100 mM of ManNAc for
48 hr.
(D) Short-term growth characteristics of Jurkat cells preincubated with 50 or 100 mM ManNAc, or without ManNAc, for 48 hr, and then cultured
in the presence of 5 at 0–4.0 mM after 5 days. Error bars are omitted for clarity; the standard deviation (SD) of the mean is less than 5 % for
three replicates.
(E) Short-term growth characteristics of Jurkat cells on Day 5 (highlight of the data in Figure 6D) at 0.5, 1.0, and 1.5 mM of 5. Error bars rep-
resent SD of at least two replicate samples.
(F) Long-term growth characteristics of Jurkat cells preincubated with ManNAc at 50 or 100 mM, or without ManNAc, for 48 hr, and then
cultured in the presence of 5 at 0–4.0 mM for 15 days. Cell densities at 1.5, 2.0, and 2.5 mM are shown. Error bars represent SD of at least
two replicate samples.
(G) Comparison of the effect of ManNAc, 5, a 4:1 molar mixture of 5 and ManNAc, or 1 on cell cycle and DNA fragmentation in Jurkat cells after
5 days of incubation studied by PI/RNase A staining.and 5, as shown in Figures 6C–6F, met with only modest
success. When combined in the same molecule, how-
ever, the concentration range (50–100 mM) where 1
shows its full range of bioactivity (i.e., apoptosis,
Figure 2A; p21WAF1/Cip1 activation, Figures 3C and 6A;
and sialic acid production, Figure 6B) compares favor-
ably with other SCFA-based drug candidates already
under clinical evaluation, such as 4 [19] or synthetic mol-
ecules that include hydroxamates, cyclic peptides, ali-
phatic acids, and benzamides [4].Mechanistic Connections between n-Butyrate,
ManNAc, and the Unique Activity of 1
Having established that ManNAc andn-butyrate must be
delivered together as a single hybrid molecule to support
the robust activation of sialic acid biosynthesis associ-
ated with apoptosis, we turned our efforts toward uncov-
ering mechanistic clues to explain how the sugar moiety
generates the unique cellular responses observed for 1.
Several factors indicate that sialic acid is involved in me-
diating the unique biological effects of 1. First, the data
Chemistry & Biology
1272Figure 7. GLYCOv3 Microarray Analysis of
the Effect of 1 and 3 on Gene Expression of
Glycan Binding Proteins
(A) The numbers of genes up- or down-regu-
lated by 2-fold or higher in MDA-MB-231
cells incubated with 1 or 3 at 125 mM for 3
days relative to ethanol-treated controls are
shown in Venn diagrams. Expression data
were obtained with the GLYCOv3 gene chip
array that contains probe sets to monitor
the expression of approximately 2000 human
and mouse transcripts relevant to glycosyla-
tion.
(B) List of genes up- or down-regulated by 1
by at least 2-fold.
(C) List of genes up- or down-regulated by 3
by at least 2-fold. The overlapping changes
in gene expression by 1 and 3 are given in
bold.presented in Figure 6 experimentally links the produc-
tion of sialic acid with sensitization of cells to butyrate.
Second, ManNAc has been described as being a dedi-
cated metabolic precursor to the biosynthesis of sialic
acid, with only one report describing a different biologi-
cal fate for this sugar; the one situation where ManNAc is
not used for sialic acid biosynthesis is that in which the
renin binding protein (RBP), which also holds epimerase
activity, converts ManNAc to GlcNAc [56]. This alternate
metabolic route for ManNAc did not apply to the current
studies, because RBP is not expressed in Jurkat cells
[56] and, even if it were, the control experiments done us-
ing 2 eliminated the possibility that the combination of
butyrate and GlcNAc could reproduce the effects of 1. Fi-
nally, a solid body of literature has emerged implicating
sialic acid and its modifications in several facets of the
apoptotic response [39–43], and it is reasonable that
the high levels of this sugar produced in cells at concen-
trations of 1 associated with apoptosis (Figure 6B) can
interfere with this complex regulatory system.
Despite this compelling indirect evidence, it will be
challenging to provide unequivocal proof for the role of
sialic acid in mediating the biological effects of 1. First,
the obvious explanation—that sialic acid has a direct ef-
fect on the genes involved in sialic acid metabolism—
has been ruled out by quantitative real-time PCR analy-
sis of ManNAc-treated cells [57]. Second, attempts to
mimic the unique effects of 1 using a 4:1 molar mixture
of 5 and ManNAc are hampered by the limited cellular
uptake of this sugar; consequently, it is not possible
to attain the high levels of sialic acid associated with
the toxicity of 1 with the free monosaccharide form of
ManNAc (Figure 6). An alternative approach to mimic
the effects of 1 by using Ac4ManNAc, which is known
to increase total sialic acid to much higher levels than
ManNAc (see [37] and Figure S3), to prime the sialic
acid biosynthesis is not helpful in resolving the individ-ual roles played by ManNAc and 5, because the intracel-
lularly released acetate (an SCFA in itself) affects the ex-
pression of sialic acid pathway genes (Figure S4 and
accompanying discussion). As a result, the specific cel-
lular effects arising from the high levels of sialic acid
supported by 1 cannot be determined in the absence
of n-butyrate or acetate. Aside from pharmacokinetic
considerations, another issue is that the two compo-
nents of 1 may interact by modulating the same mole-
cules involved in apoptosis—for example, both sialic
acid [39] and n-butyrate [58, 59] modulate the sensitivity
of cancer cells to anti-Fas-mediated apoptosis.
Unraveling the specific contributions of butyrate to
the overall activity of 1 is likely to be as complex as for
sialic acid, and will require much work beyond the cur-
rent report. However, as a clue to guide further investi-
gation, and to emphasize the powerful ability of the
core monosaccharide to modulate SCFA activity, we
further investigated the repercussions—beyond the
hallmark changes to p21WAF1/Cip1 expression associ-
ated with SCFAs—of the differential effects of 1 and 3
on histone acetylation (Figure 3A). Following the strat-
egy reported by Williams and coworkers to uncover
the combined effects of n-butyrate and sulindac or cy-
cloheximide by genomic analysis [60], we undertook a
focused microarray study of glycan binding proteins
(using the GLYCOv3 chip developed by The Consortium
for Functional Glycomics [61]) on the effects of 1 and 3
compared to ethanol-treated controls in the human
breast cancer MDA-MB-231 line. This experiment
showed that, although a common set of genes was reg-
ulated by both compounds, consistent with the pres-
ence of the common moiety butyrate, there was consid-
erable variation in the overall pattern of gene expression
(Figure 7), thereby, once again, clearly illustrating the ca-
pacity of the core sugar to influence the overall cellular
response to SCFAs.
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compelling evidence that the sugar-specific effects of
1 occur via a complex interplay involving sialic acid
metabolism and the effects of butyrate on histone acet-
ylation, other mechanistic explanations remain open.
For example, currently unknown metabolic fates for
ManNAc (other than the priming of sialic acid biosynthe-
sis) may exist. Alternately, an intriguing possibility is
that HDACi activity occurs before complete removal of
n-butyrates from the sugar core structure. Then, based
on the precedent of where n-butyrate, 4PB, and trichos-
tatin have different activity profiles by virtue of the
chemical context of the butyrate moiety itself [5], a par-
tially butyrated derivative of mannose would be ex-
pected to have a different effect on gene expression
compared with a partially butyrated derivative of
ManNAc and, thereby, to account for the differences in
gene expression between 1 and 3 (Figure 7).
Conclusions
Regardless of the precise mechanisms involved, the de-
tailed elucidation of which is beyond the scope of this
study, we have presented experimental evidence in sup-
port of the intriguing strategy that the HDACi activity ofn-
butyrate can be tuned by the monosaccharide core that
was, in the past, only designed to be an innocuous deliv-
ery vehicle. Importantly, we showed that neither ManNAc
nor n-butyrate, the constituent components of 1, when
supplied as separate molecules, could initiate apoptosis
at therapeutically relevant concentrations. As such, this
emphasizes the need to combine both functionalities in
a single hybrid molecule. In conclusion, we believe that
our approach of combining glycosylation with HDACi
constitutes an important contribution to the recent flurry
of butyrate-based anticancer research that has been
compared to putting ‘‘old wine in new bottles’’ [62].
Significance
Lossofcell cycle checkpoint control andabnormalgly-
cosylation are two of the major cellular aberrations as-
sociated with cancer. Multiple strategies to correct de-
fects in cell cycle checkpoints arising from abnormal
histone-chromatin interactions are now under investi-
gation, including intense efforts to develop histone de-
acetylase inhibitors (HDACi), such asbutyrate. By con-
trast, glycosylation-targeted cancer therapies have
been slow to emerge. To meet this void, we synthe-
sized butyrate-hexosamine hybrids that target both
gene regulation and glycoconjugate expression and,
by enhancing bioactivity by a sugar-dependent mech-
anism, ensure both the ‘‘arrest’’ and ‘‘execution’’ of
cancer cells. Narrowly, this work provides a promising
approach to complement the anticancer potential of
butyrate; broadly, it provides a concrete example
of bringing glycosylation-based therapies closer to
reality.
Experimental Procedures
Cell Culture Methods and Supplementation with Butyrate
Derivatives 1–5
For cell culture studies, But4ManNAc (1) [44] was used as a mixture
of anomers (a/b = 10/90), But4GlcNAc (2) as pure a-anomer, andBut5Man (3) as pure b-anomer (the intracellular hydrolysis of buty-
rate esters makes the anomeric configuration less relevant in these
studies, and we found similar cellular toxicity effects between the a-
and b-anomers). Stock solutions of the analogs were made in etha-
nol at 10 and 50 mM. In the case of cells growing in suspension, the
solutions of 1–4 (or an ethanol control at an equivalent volume) were
coated onto dishes, and the ethanol was allowed to evaporate prior
to the addition of cells. Unless otherwise noted, throughout this
study, Jurkat cells (Clone E-6; ATCC, Manassas, VA) were cultured
in RPMI 1640 medium supplemented with 300 mg/l glutamine,
5.0% fetal bovine serum (FBS; HyClone, Logan, Utah) and 1.0% of
a 1003 pen/strep (P/S) stock solution containing penicillin (100
units/ml) and streptomycin (100 mg/ml); HL-60 cells (ATCC) were cul-
tured in RPMI 1640 medium supplemented with 10% FBS and pen/
strep; and AD293 (HEK), HeLa, and MDA-MB-231 cells (Stratagene,
La Jolla, CA) were grown in DMEM medium with 10% FBS and pen/
strep. In all cases, cells were incubated at 37C in a 5.0% CO2,
water-saturated environment. Cell counting was performed with a
Beckman Coulter Z2 particle counter (Beckman Coulter, Fullerton,
CA) and hemacytometer.
Toxicity and Growth Inhibition Assays
Solutions of the analogs in EtOH (10 mM stock) were coated onto 24-
well plates at a range of concentrations from 0 to 320 mM, and etha-
nol was allowed to evaporate. Jurkat cells (1.0 3 105) in 0.5 ml of
medium were added to each well on Day 0. On Days 3 and 5, fresh
medium (1.0 ml) was added to each well, cell cultures were mixed
by gentle pipetting, and 100 ml of cell suspension from each well
was counted. On Days 7, 9, 11, 13, and 15, 1.0 ml of cell suspension
was removed from each well after thorough mixing, and fresh me-
dium (1.0 ml) was added. Cells counts from Days 3, 5, and 15 were
plotted as a percentage of control.
Western Analysis of Histone H3 Acetylation
The acetylation of histone H3 was analyzed by western blotting.
Briefly, 2.0 3 106 HeLa cells were plated in 10 ml of DMEM medium
supplemented with 10% FBS and 1% P/S in 10 cm T.C. dishes. After
24 hr, the medium was changed, and the cells were treated with ei-
ther 40 ml ethanol, 5 (to give a final concentration of 2.0 mM), or 1, 2,
3, and 4 (200 mM). After 5 days, the cells were harvested using a cell
scraper, washed with PBS (2 3 5.0 ml), resuspended in 400 ml lysis
buffer (100 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,
1.5 mM PMSF), treated with 100 ml 1.0 N hydrochloric acid, vortexed,
and kept overnight at 2C. The lysate was centrifuged at 11,000 3 g
at 4C for 10 min, and the supernatant was collected carefully
and stored at 280C. Protein concentration was estimated using
Coomassie plus reagent (Pierce, Rockford, IL). SDS-PAGE was per-
formed on 18% gels (Ready Gel; Bio-Rad, Hercules, CA) with 10 mg
of protein lysate, and blotted to nitrocellulose membrane. The mem-
branes were stained with anti-histone H3 (total H3; mouse monoclo-
nal IgG1k, Cat. No. 05-499, 1:500; Upstate, Lake Placid, NY) and anti-
acetylhistone H3 (rabbit antiserum, Cat. No. 07-353, 1:1000; Up-
state), detected using HRP-linked affinity-purified horse anti-mouse
IgG (heavy and light chains [H&L], cat. no. 7076) and affinity-purified
goat anti-rabbit IgG (H&L, cat. no. 7074, 1:20,000; Cell Signaling
Technology, Inc., Danvers, MA), respectively, and enhanced chem-
iluminescence reagents (Supersignal West Dura Extended Duration
substrate; Pierce). At least two replicate gels were performed,
scanned, and the band density quantified using ImageJ (National
Institutes of Health, Bethesda, MD), and the results presented as
the ratio of acetylated histone H3 to total histone H3.
Assay for Total Sialic Acid Production
Jurkat cells (5.03 106 cells in 10 ml medium) were incubated with 1–
5 at various concentrations. After 3 days, the cells (1.0 3 106 per
sample) were lysed by three freeze-thaw cycles. The cell lysates
were analyzed by using an adapted version of the periodate-resor-
cinol assay [37, 63], with the periodic acid oxidation step performed
on ice for quantification of total (i.e., free monosaccharide plus gly-
coconjugate bound) sialic acid. For each assay, a standard curve
was obtained usingN-acetylneuraminic acid (Pfanstiehl, Waukegan,
IL) for calibration.
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Supplemental Data, including detailed experimental procedure for
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